Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

NCT06715514 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how menopausal hormone therapy and GLP-1 agonists affect blood sugar and energy balance in postmenopausal women who have type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 96 people Planned (estimated).

Who can join Ages 18+ · female only

Timeline Started 2025-02 · est. completion 2026-08

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT06715514 ↗

Description as written by the study sponsor.

The overall aim is to investigate the hypothesis that restoring E2 levels through MHT improves glucose and energy homeostasis and potentiates the beneficial effects of GLP-1RA in early postmenopausal women with pre- or existing type 2 diabetes. The primary objective is to assess the efficacy of combined MHT and GLP-1RA in improving glucose control in early postmenopausal women with pre- or existing type 2 diabetes, compared to GLP-1RA alone. Secondary objectives include efficacy analyses on body weight, other measures of cardiometabolic health, lifestyle behaviour, menopausal symptoms, and the exploration of mechanisms underpinning potential glycaemic and weight control benefits, and biomarkers of haemostasis.

Treatments tested

GLP-1 Receptor Agonist also known as Semaglutide Drug

Wegovy®
Menopausal Hormone Therapy also known as Estradiol, Micronized Progesterone Drug

Estradot® and Utrogestan®\* (in women with intact uterus\*)

Main thing measured	Change in HbA1C
Sponsor	Lia Bally
Conditions studied	Menopause, Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06715514 ↗